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The Selective 5-HT2A Receptor Antagonist M100907
Enhances Antidepressant-Like Behavioral Effects of the
SSRI Fluoxetine
Gerard J Marek*,1, Raul Martin-Ruiz2, Allyson Abo1 and Francesc Artigas2
1Department of Psychiatry, Yale School of Medicine, Connecticut Mental Health Center and the Ribicoff Research Facilities, New Haven, CT,
USA; 2Department of Neurochemistry, Institut d’Investigacions Biome`diques de Barcelona, CSIC (IDIBPAS), Barcelona, Spain
The addition of low doses of atypical antipsychotic drugs, which saturate 5-HT2A receptors, enhances the therapeutic effect of selective
serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) in patients with major depression as well as treatment-refractory
obsessive-compulsive disorder. The purpose of the present studies was to test the effects of combined treatment with a low dose of a
highly selective 5-HT2A receptor antagonist (M100907; formerly MDL 100,907) and low doses of a SSRI using a behavioral screen in
rodents (the differential-reinforcement-of low rate 72-s schedule of reinforcement; DRL 72-s) which previously has been shown to be
sensitive both to 5-HT2 antagonists and SSRIs. M100907 has a B100-fold or greater selectivity at 5-HT2A receptors vs other 5-HT
receptor subtypes, and would not be expected to appreciably occupy non-5-HT2A receptors at doses below 100 mg/kg. M100907
increased the reinforcement rate, decreased the response rate, and shifted the inter-response time distributions to the right in a pattern
characteristic of antidepressant drugs. In addition, a positive synergistic interaction occurred when testing low doses of the 5-HT2A
receptor antagonist (6.25–12.5mg/kg) with clinically relevant doses of the SSRI fluoxetine (2.5–5 mg/kg), which both exerted minimal
antidepressant-like effects by themselves. In vivo microdialysis study revealed that a low dose of M100907 (12.5 mg/kg) did not elevate
extracellular 5-HT levels in the prefrontal cortex over those observed with fluoxetine alone (5 mg/kg). These results will be discussed in
the context that the combined blockade of 5-HT2A receptors and serotonin transporters (SERT) may result in greater efficacy in treating
neuropsychiatric syndromes than blocking either site alone.
Neuropsychopharmacology (2005) 30, 2205–2215. doi:10.1038/sj.npp.1300762; published online 11 May 2005
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INTRODUCTION
Blockade of the serotonin (5-hydroxytryptamine; 5-HT)
transporter (SERT) is the common pharmacological action
shared by selective serotonin reuptake inhibitors (SSRIs; eg
citalopram, escitalopram, fluoxetine, fluvoxamine, parox-
etine, sertraline), approved by regulatory agencies for the
treatment of mood and anxiety disorders. Enhancement of
5-HT synaptic availability appears to be a critical compo-
nent of the mechanism underlying the action of SSRIs in the
treatment of depression as demonstrated by the tryptophan
depletion paradigm (Delgado et al, 1990, 1999). However,
there are at least 14 known 5-HT receptors in the brain
(excluding splice variants and edited isoforms). Remarkably
little is known regarding which 5-HT receptors are involved
(positively and negatively) in the therapeutic effects of
SSRIs over a diverse range of neuropsychiatric syndromes
such as major depression, bipolar depression, obsessive-
compulsive disorder (OCD), panic disorder, generalized
anxiety disorder (GAD), post-traumatic stress disorder
(PTSD), social anxiety disorder, and pervasive develop-
mental disorders.
A growing body of clinical psychopharmacological
evidence is consistent with the hypothesis that blockade of
5-HT2A receptors might enhance the therapeutic effective-
ness of SSRIs. First and foremost, a number of placebo-
controlled trials have found that addition of drugs, which
share a common pharmacological action of 5-HT2 receptor
blockade (eg, mianserin, mirtazapine, and olanzapine),
appear to enhance the antidepressant efficacy of SSRIs
(Marek et al, 2003). Several open-label reports have further
suggested that low doses of the atypical antipsychotic drug
risperidone (0.5–1 mg/day), which shows B30-fold 5-HT2A
vs 5-HT2C selectivity, results in a rapid decrease in
depressive symptoms in depressed patients when initiated
with SSRI treatment or when added to ongoing SSRI
treatment (Hirose and Ashby, 2002; O’Connor and Silver,
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1998; Ostroff and Nelson, 1999). These studies would be
consistent with the hypothesis that activation of 5-HT2A
receptors acts in opposition to activation of critical non-
5-HT2A receptors and the cascade of events leading to
therapeutic efficacy.
One strategy to explore potential 5-HT receptor interac-
tions is to study animal models of depression or
antidepressant drug screens. The differential-reinforce-
ment-of low rate 72-s (DRL 72-s) schedule is a screen for
antidepressant drugs that is sensitive both to 5-HT2
receptor antagonists and SSRIs (Marek and Seiden, 1988;
Seiden et al, 1985; Sokolowski and Seiden, 1999). Rats
performing under a DRL 72-s schedule are required to
withhold responses for at least 72 s following the previous
response in order to receive a reinforcer. Theoretically,
drugs may increase the number of reinforcers obtained and
induce rightward shifts in inter-response time (IRT)
distributions in rats performing under a DRL 72-s schedule
by either altering temporal discrimination or enhancing
the ability of rats to withhold inappropriate responses
(O’Donnell et al, 2005).
The first purpose of the present studies, given the
considerable pharmacological overlap between different
members of the 5-HT2 family of receptors, was to test for
antidepressant-like effects on the DRL 72-s schedule of a
highly selective 5-HT2A receptor antagonist (M100907;
formerly MDL 100,907), at doses that are known to be
selective for the 5-HT2A receptor (Kehne et al, 1996). The
second purpose was to test whether a synergistic interaction
may occur on DRL 72-s behavior between a 5-HT2A receptor
antagonist and an SSRI by examining administration of
several doses of M100907 and fluoxetine that are relatively
inactive alone. Third, an in vivo dialysis study was
conducted to examine whether administration of relatively
low doses of the 5-HT2A receptor antagonist M100907
elevated prefrontal extracellular 5-HT levels over that seen
with fluoxetine administration.
MATERIALS AND METHODS
Subjects
A total of 23 male Sprague–Dawley rats weighing between
300 and 350 g at the beginning of the behavioral experi-
ments (Holtzman, Madison, WI) were housed in suspended
stainless steel wire cages (18 36 20 cm) with two rats
occupying each cage. The colony room was maintained at
201C and relative humidity (60%). The room was illumi-
nated 12 h/day (0700–1900 hours). All rats had free access to
laboratory chow (Teklad 4% Rat Diet) except during
experimental sessions. Water was available for a 20 min
period following the daily behavioral session. The principles
of laboratory animal care (NIH publication No. 85–23,
revised 1985) were followed.
In total,24 male albino Wistar rats (Iffa Credo, Lyon,
France) weighing 280–320 g were employed for the in vivo
microdialysis experiments. The colony room was main-
tained at 22721C. Food and water were provided ad libitum
before and during experiments. Animal care followed the
European Union Regulations (O.J. of E.C. L358/1 18/12/
1986) and procedures were approved by the local Ethics
Committee.
Apparatus
Eight MED Associates operant-conditioning chambers
(30.5 24.1 29.2 cm; St Albans, VT; www.med-associates.-
com) were used for the DRL experiments. The lever in these
chambers was mounted on one wall with the water access
next to the lever in the middle of the wall. A reinforced
response caused the dipper (0.02 cc cup) to be lifted from a
water trough to an opening in the floor of the access port for
4 s. The houselight (which was mounted on the opposite
wall) was turned on when the session began, remained on
throughout the entire session and turned off at the end of
the session. Each experimental chamber was enclosed in a
melamine sound-attenuating cubicle and equipped with a
white noise generator to provide masking noise.
Operant Training
Rats were water deprived for B22.5 h before each session.
Each rat was initially trained under an alternative fixed ratio
1, fixed-time 1 min schedule for water reinforcement. Thus,
each response was reinforced and water was also provided
every minute if a response did not occur. The few rats that
did not acquire lever-pressing behavior after three daily 1 h
sessions under this schedule were trained by the experi-
menter using the method of successive approximation.
After the rats had acquired lever-pressing behavior, they
were trained during daily DRL 18-s sessions for B2 weeks
before moving directly to DRL 72-s sessions. The respond-
ing on these sessions became stable after B8 weeks.
Experimental sessions lasted for 1 h and were conducted 5
days/week during light hours.
Surgery and Microdialysis Procedures
An updated description of the microdialysis procedures has
been published (Adell and Artigas 1998). Rats were
anesthetized with pentobarbital (60 mg/kg i.p.) and con-
centric dialysis probes were implanted in the prefrontal
cortex (PFC). Two different locations were chosen to target
mainly layers 3–5 (medial PFC, mPFC) and layer 6 (lateral
PFC, lPFC). Probes were secured to the skull with anchor
screws and dental cement. Dialysis membranes were made
from hollow Cuprophan fibers with 252 mm OD, 220 mm ID,
and a nominal 5000-Da molecular weight cutoff (GFE09,
Gambro, Lund, Sweden). The active zone in the probes was
4 mm long. The stereotaxic coordinates were AP þ 3.4, DV
6.0; L 0.8 (mPFC) or L 2.5 mm (lateral PFC; lPFC).
They were taken from bregma and dura mater according to
the rat brain atlas of Paxinos and Watson (1986). Another
group of rats was implanted with probes in the dorsal
striatum (AP þ 0.2, DV 8.0, L 3.0). Rats were allowed to
recover from anesthesia in the dialysis cages (cubic, 40 cm
each side) and 20–24 h later the probes were perfused with
artificial CSF (aCSF; composition: NaCl 125 mM, KCl
2.5 mM, MgCl2 1.18 mM, and CaCl2 1.26 mM; pH 6.5–7.0)
at 1.5 ml/min. Dialysate samples of 30 ml were collected at
20-min intervals into polypropylene microcentrifuge vials.
After an initial 1 h, sample of dialysate was discarded, four
fractions were collected to obtain basal values before drug
administration. At the end of the experiments, rats were
killed by an overdose of sodium pentobarbital. The
5-HT2A antagonist and SSRI interactions
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placement of the dialysis probes was checked by perfusing
Fast Green dye and examination of the probe track after
cutting the brain at the appropriate level. Only animals with
probes correctly placed were included in the calculations.
5-HT was analyzed by a modification of a high-
performance liquid chromatography method previously
described in an updated form (Adell and Artigas, 1998).
5-HT was separated on a 3mm ODS 2 column
(7.5 cm 0.46 cm; Beckman, San Ramon, CA) and detected
amperometrically with a Hewlett Packard 1049 detector set
at the potential of þ 0.6 V. Retention time was 3.5–4 min.
The detection limit for 5-HT was typically 1 fmol/sample.
Dialysate 5-HT values were calculated by reference to
standard curves run daily.
Schedule Control and Statistical Analyses
The experimental chambers were connected to a PC via an
MED-SYS-8 interface and software package. All behavioral
data are expressed as the mean7SEM normalized to the
vehicle or vehicle–vehicle condition. The data analysis
was performed on the raw data. The effects of M100907
(3.25–100mg/kg) and fluoxetine (2.5–10 mg/kg) alone were
analyzed with a one-factor repeated measures analysis of
variance (ANOVA). The effects of the combined treatment
of M100907 and fluoxetine were analyzed with a two-factor
repeated measures AOVA using M100907 and fluoxetine as
within-subject factors. Significant main effects or interac-
tions were analyzed by the Newman–Keuls or Dunnett
test, where appropriate. The level of significance was set
for po0.05 for all analyses.
The IRT distribution for each individual rat was analyzed
with the nonparametic Kolmogorov–Smirnov test to make
within-subject comparisons between different treatment
conditions. The level of significance was conservatively set
for po0.001, even though only a limited set of a priori
comparisons were planned.
Microdialysis results are expressed as femtomoles per
fraction (uncorrected for recovery) and shown in figures as
percentage of basal values (individual means of four
predrug fractions). Statistical analysis of drug effects on
dialysate 5-HT was performed using one-or two-factor
repeated measures ANOVA with time as the repeated factor
and drug as an independent factor.
Drugs
Doses were calculated on the basis of the salt forms. The
drugs were dissolved in saline, neutralized to a pHB7.4,
and injected i.p. in a volume of 1 ml/kg body weight.
M100907 was a gift from Marion Merrell Dow (Cincinnati,
OH; now Sanolfi-Aventis) and fluoxetine was a gift from Eli
Lilly and Company (Indianapolis, IN). Drugs were adminis-
tered to the animals only once weekly in an ascending order
of dose magnitiude (Thursday) to minimize possible
carryover effects since a majority of 5-HT2A receptor
antagonists have been associated with 5-HT2A receptor
downregulation. In experiments where both fluoxetine and
M100907 were administered, dose–response determinations
for fluoxetine alone and M100907 alone were obtained
concurrently with the combination such that fluoxetine
10 mg/kg–vehicle, vehicle–M100907 (25 mg/kg), and vehi-
cle–M100907 (50 mg/kg) were examined after all combina-
tions of the two drugs had been tested. Behavior returned to
baseline the day following drug administration.
RESULTS
Antidepressant-Like Action of M100907 on DRL 72-s
Behavior
Since most atypical antidepressants (which do not appre-
ciably block monoamine uptake or monoamine oxidase,
MAO) share considerable potency at both 5-HT2A and 5-
HT2C receptors, we examined a highly selective antagonist
for 5-HT2A vs 5-HT2C receptors. M100907 exerted a dose-
dependent (3.12–1000 mg/kg, i.p.) increase in the reinforce-
ment rate (F(8,40)¼ 5.83, po0.001; Figure 1) and decrease
in the total response rate (F(8,40)¼ 3.89, po0.01; Figure 1),
similar to the effects of tricyclic antidepressants. The ED50
for the changes in the reinforcement and response rates was
B12 mg/kg calculated by nonlinear curve fitting (Delta
Graph, not shown). The maximal increase in the reinforce-
ment rate and decrease in the response rate occurred at
100 mg/kg. Interestingly, the magnitude of changes in the
reinforcement and response rate was numerically smaller at
the 300 and 1000 mg/kg doses than the 100 mg/kg dose.
Overall, there appears to be pproximately a 25-fold
selectivity between the ED50 for increasing the reinforce-
ment rate and the first dose of M100907 with an appreciable
submaximal effect (300 mg/kg, i.p.).
Examination of the IRT distributions revealed that
M100907 resulted in a cohesive shift to the right in the
IRT distribution (Figure 2), similar to the effects of TCAs,
MAOIs, and atypical antidepressants. Compared to the
vehicle condition, a significantly different IRT distribution
(po0.001, Kolmogorov–Smirnov test) with an increased
mean IRT was associated with the following M100907 doses
Figure 1 Dose-dependent changes in the frequency of reinforcers and
total responses induced by the 5-HT2A receptor antagonist M100907 (3.13–
1000mg/kg, i.p.) for male Sprague–Dawley rats performing on a DRL 72-s
schedule. The increased reinforcement rate is shown in squares, while the
decreased response rate is displayed with circles. For the vehicle–vehicle
condition, the mean (7SEM) number of reinforcers obtained was 10.6
(72.2), while the mean (7SEM) number of total responses was 74.9
(78.2). Rats were injected (i.p.; 1 ml/kg, n¼ 7) 1 h prior to a 1 h behavioral
session. The maximal change in the reinforcement and total response rate
occurred at the 100mg/kg dose, while the ED50 for the increase in the
reinforcement rate was 12mg/kg (Delta Graph, not shown). Significant
changes from the vehicle control are indicated for po0.05, * and po0.01, **.
5-HT2A antagonist and SSRI interactions
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(6.25 mg/kg, one of eight rats; 12.5 mg/kg, one of eight; 25 mg/
kg, two of eight; 50 mg/kg, three of eight; 100 mg/kg, four of
eight; 300 mg/kg, three of eight; 1000 mg/kg, zero of eight).
Interaction between M100907 and Fluoxetine on DRL
72-s Behavior
We next examined the interaction of low doses of both
M100907 and fluoxetine using a different group of eight
subjects in order to specifically test for an interaction
between the effects of simultaneously blocking 5-HT2A
receptors and SERT. Fluoxetine (2.5–10 mg/kg, i.p.) exerted
significant increases in the reinforcement rate (F(3,21)¼
10.59, po0.001; Figure 3) only at the highest dose tested
(226725.2% of vehicle control; mean7SEM; not shown)
consistent with previous results. Higher doses were not
tested as the 10 mg/kg dose appears to result in maximal
effects on DRL behavior as it also does for elevation of
prefrontal extracellular 5-HT levels (Hervas and Artigas, 1998).
Fluoxetine alone did not significantly reduce the total
response rate (Figure 3; F(3,21)¼ 1.85, p¼ 0.17).
Typical examples for the effects of fluoxetine on the IRT
distribution are shown for several rats in Figure 5.
Compared to the vehicle–vehicle condition, no effects were
observed on the IRT distributions for most of the subjects.
Significant differences in the IRT distribution associated
with an increased mean IRT occurred in 0, 0, and two rats
(out of eight total) for the 2.5, 5, and 10 mg/kg fluoxetine
doses, respectively. Significant differences in the IRT
distribution (associated with a decreased mean IRT)
occurred only at the 2.5 mg/kg dose where three out of
eight subjects had a significant change in the IRT
distribution compared to the control condition where there
was a decrease in the mean IRT.
The maximal dose of M100907 tested for animals used in
the drug interaction experiment was 50 mg/kg. There was a
significant overall effect for M100907 on the reinforcement
rate (Figure 3; F(4,28)¼ 3.39, po0.05) but not the response
rate (Figure 3; F(4,28)¼ 1.90, p¼ 0.14). The lowest two
doses (6.12 and 12.5 mg/kg) did not significantly alter the
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Figure 2 Effects of the selective 5-HT2A receptor antagonist M100907
(25–100 mg/kg) on inter-response time (IRT) distributions for rats
performing on a DRL 72-s schedule. The effects for two rats are shown
where a rightward shift (typical of most antidepressant drugs) in the IRT
distribution occurred compared to the vehicle condition. For rat 61 and 65,
significant changes from the vehicle condition occurred at each of the three
doses shown (po0.001, Kolmogorov–Smirnov test). The mean IRT for the
conditions shown for rat 61 was 46.6 s (vehicle, SD 30.7); 72.5 (25 mg/kg,
SD 49.9); 68.4 (50 mg/kg, SD 30.7); 124.1 (100mg/kg, SD 118.1). The mean
IRT for the conditions shown for rat 65 was 55.2 s (vehicle, SD 18.0); 71.2
(25 mg/kg, SD 22.1); 71.7 (50 mg/kg, SD 22.0); 78.6 (100 mg/kg, SD 21.0).
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Figure 3 Dose-dependent changes in the frequency of reinforcers (top)
and responses (bottom) induced by combinations of the 5-HT2A receptor
antagonist M100907 (6.25 or 12.5mg/kg or vehicle, i.p.) and fluoxetine (2.5
or 5 mg/kg or vehicle) for rats (n¼ 8) performing on a DRL 72-s schedule.
For the vehicle–vehicle condition, the mean (7SEM) number of reinforcers
obtained was 6.5 (70.9). For the vehicle–vehicle condition, the mean
(7SEM) number of total responses made was 88 (73.7). Rats were
injected (i.p.; 1 ml/kg, n¼ 8) 1 h prior to a 1 h behavioral session. Significant
changes from the vehicle control are indicated for po0.05, * and po0.01,
**. Significant changes from the respective M100907-vehicle or vehicle–
fluoxetine condition were indicated by either ‘m’ or ‘f’ for po0.05.
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behavior of the rats performing on the DRL 72-s schedule.
Higher doses (25 and 50 mg/kg, i.p., not shown) did
significantly increase the reinforcement rate (171718 and
165726% of vehicle–vehicle control, respectively) and
nonsignificantly decreased the response rate (9375 and
9378% vehicle–vehicle control, respectively).
The combined administration of M100907 and fluoxetine
resulted in substantial increases in the reinforcement rate
and decreases in the response rate that were greater than the
combined effects of the two drugs independently. For the
reinforcement rate, significant main effects of M100907
(F(2,14)¼ 45.15, po0.001) and fluoxetine (F(2,14)¼ 31.43,
po0.001) were present together with a significant interac-
tion effect (F(4,28)¼ 3.63, po0.05). Three of the four com-
bined doses of the two drugs tested (M100907, 6.25 mg/kgþ
fluoxetine, 5 mg/kg; M100907, 12.5 mg/kgþ fluoxetine,
2.5 mg/kg; M100907, 12.5 mg/kgþ fluoxetine, 5 mg/kg) were
significantly different from the effects of both the respective
dose of M100907 alone or fluoxetine alone (Newman–Keuls,
po0.01).
For the total response rate, significant main effects of
M100907 (F(2,14)¼ 4.16, po0.05) and fluoxetine (F(2,14)¼
6.28, po0.05) and a significant interaction effect (F(4,28)¼
8.41, po0.001) were present (Figure 4). All four combined
doses of these two drugs tested were significantly different
from the effects of the respective M100907 or fluoxetine
dose alone or the vehicle–vehicle condition (po0.05)
except for the combination of M100907 (12.5 mg/kg) and
fluoxetine (2.5 mg/kg).
The comparison of the IRT distributions for the
combination of M100907 and fluoxetine vs the vehicle–
vehicle condition confirms the synergistic interaction
between these two drugs (Figures 4 and 5). This synergistic
interaction was most apparent for the combination of the
highest dose of M100907 and fluoxetine tested where four of
eight rats had an IRT distribution that was significantly
different (po0.001, Kolmogorov–Smirnov test; and asso-
ciated with an increased mean IRT) than the vehicle–vehicle
condition. In contrast, only one of eight subjects adminis-
tered the same 12.5 mg/kg dose of M100907 alone had a
significantly different IRT distribution than the vehicle–
vehicle condition, and in this subject the mean IRT was
decreased. None of eight subjects administered fluoxetine
(5 mg/kg) had a significantly different IRT distribution that
was associated with an increased mean IRT compared to the
vehicle–vehicle condition (Figure 4). Furthermore, five of
eight rats administered the combination of M100907
(12.5 mg/kg) and fluoxetine (5 mg/kg) had a significantly
different IRT distribution (associated with an increased
mean IRT) compared to the vehicle–fluoxetine (5 mg/kg)
condition. Similarly, four of eight rats administered the
combination of M100907 (12.5 mg/kg) and fluoxetine (5 mg/
kg) had a significantly different IRT distribution (associated
with an increased mean IRT) compared to the M100907
(12.5 mg/kg)–vehicle condition.
This apparent synergistic effect between fluoxetine and
M100907 on the IRT distributions was also highlighted
by comparison of the M100907 (12.5 mg/kg)–fluoxetine
(2.5 mg/kg) condition to the vehicle–vehicle condition or
the vehicle–fluoxetine (2.5 mg/kg) condition (not shown).
While the vehicle–fluoxetine (2.5 mg/kg) condition was
associated with three of eight rats demonstrating significant
changes (po0.001, Kolmogorov–Smirnov test) in the IRT
distribution compared to the vehicle–vehicle condition
(decreased mean IRT), the combination of M100907
(12.5 mg/kg) and fluoxetine (2.5 mg/kg) was associated with
four of eight rats, demonstrating significant changes in the
IRT distribution compared to the vehicle–vehicle condition
(increased mean IRT). While only one of eight rats
demonstrated a significant change (po0.001) in the IRT
distribution for the M100907 (12.5 mg/kg)–fluoxetine
(2.5 mg/kg) condition compared to the M100907 (12.5 mg/
kg)–vehicle condition (associated with an increased mean
IRT), an additional four of eight subjects administered the
combination of M100907 (12.5 mg/kg ) and fluoxetine
(2.5 mg/kg) exhibited a trend towards a significantly
different IRT distribution (po0.005, associated with an
increased mean IRT).
A replication of this experiment in a second group of
subjects confirmed that there was at least an additive
antidepressant-like effect of the M100907 and fluoxetine
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Figure 4 Effects of the SSRI fluoxetine (2.5–10 mg/kg) on inter-response
time (IRT) distributions for rats performing on a DRL 72-s schedule. For
rats 75 and 77, no significant changes from the vehicle condition occurred
for the three doses shown (po0.001, Kolmogorov–Smirnov test). The
5 mg/kg dose administered to rat 75 exhibited a trend towards a significant
difference from the vehicle control with an decreased mean IRT
(po0.005). The mean IRT for the conditions shown for rat 75 was
65.5 s (vehicle, SD 22.6); 61.0 (2.5 mg/kg, SD 18.8); 55.3 (5 mg/kg, SD 19.5);
62.1 (10 mg/kg, SD 15.8). The mean IRT for the conditions shown for rat
77 was 42.6 s (vehicle, SD 18.5); 34.0 (2.5 mg/kg, SD 25.0); 41.8 (5 mg/kg,
SD 23.1); 45.3 (10 mg/kg, SD 25.2).
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in rats performing on the DRL 72-s schedule. Fluoxetine
(2.5–10 mg/kg) did not significantly increase the reinforce-
ment rate or decrease the response rate, although the
reinforcement rate was nonsignificantly increased to 149%
of control at the 5 (Table 1) and 10 mg doses (not shown).
M100907 (6.25–50 mg/kg) did not significantly increase the
reinforcement rate but did significantly decrease the
response rate (F(4,28)¼ 6.62). When examining the effects
of M100907 (6.25–12.5 mg/kg) and fluoxetine (2.5–5 mg/kg),
a significant main effect for fluoxetine (F(2,14)¼ 5.28,
po0.05) and M100907 (F(2,14)¼ 8.33, po0.01) and a trend
towards an interaction effect (F(4,28)¼ 2.51, p¼ 0.06) on
reinforcers were observed. The only data points signifi-
cantly different from the vehicle–vehicle condition were for
the M100907 (6.25 mg/kg)–fluoxetine (2.5 mg/kg); M100907
(6.25 mg/kg)–fluoxetine (5 mg/kg); and M100907 (12.5 mg/
kg)–fluoxetine (5 mg/kg) combinations. The combination of
the higher doses of M100907 and fluoxetine tested were also
significantly greater than the M100907 (12.5 mg/kg)–vehicle
condition or the vehicle–fluoxetine (5 mg/kg) condition.
When examining the effects of M100907 (6.25–12.5 mg/kg)
and fluoxetine (2.5–5 mg/kg) on the total response rate, a
significant main effect for M100907 (F(2,14)¼ 17.61,
po0.001), but not for fluoxetine (po0.1), was observed
(Table 2). The interaction effect was not significant.
The comparison of the IRT distributions for the
combination of M100907 and fluoxetine vs the vehicle–
vehicle condition in this second group of subjects, like in
the previous group, suggests a synergistic interaction
between these two drugs (Figure 6). Thus, all eight rats
administered the combination of M100907 (12.5 mg/kg) and
fluoxetine (5 mg/kg) had an IRT distribution that was
significantly different (po0.001, and associated with an
increased mean IRT) than the vehicle–vehicle condition. In
contrast, zero of eight subjects administered the same
12.5 mg/kg dose of M100907 alone had a significantly
different IRT distribution than the vehicle–vehicle condi-
tion. Only two of eight subjects administered fluoxetine
(5 mg/kg) had a significantly different IRT distribution
(associated with an increased mean IRT) compared to the
vehicle–vehicle condition. Furthermore, three of eight rats
administered the combination of M100907 (12.5 mg/kg) and
fluoxetine (5 mg/kg) had a significantly different IRT
distribution (associated with an increased mean IRT)
compared to the vehicle–fluoxetine (5 mg/kg) condition.
Similarly, three of eight rats administered the combination
of M100907 (12.5 mg/kg) and fluoxetine (5 mg/kg) had a
significantly different IRT distribution (associated with an
increased mean IRT) compared to the M100907 (12.5 mg/
kg)–vehicle condition.
Table 1 Reinforcers (% of Control; Mean7SEM) Following
Treatment with Fluoxetine or Vehicle and M100907 or Vehicle
Condition Vehicle 6.25 lg/kg M100907 12.5 lg/kg M100907
Vehicle 100727 131721 124724
2.5 mg/kg fluoxetine 124725 155731* 128727
5 mg/kg fluoxetine 145727 169723* 209729**,mf
*Significantly different from vehicle–vehicle, po0.05.
**Significantly different from vehicle–vehicle, po0.001.
m, Significantly different from respective M100907 dose alone.
f, Significantly different from respective fluoxetine dose alone.
Table 2 Total Responses (% of Control; Mean7SEM) Following
Treatment with Fluoxetine or Vehicle and M100907 or Vehicle
Condition Vehicle 6.25 lg/kg M100907 12.5 lg/kg M100907
Vehicle 10077 8279* 8977
2.5 mg/kg fluoxetine 8679* 7779* 82711*
5 mg/kg fluoxetine 8876 7876* 7874*
*Significantly different from vehicle–vehicle, po0.05.
**Significantly different from vehicle–vehicle, po0.001.
m, Significantly different from respective M100907 dose alone.
f, Significantly different from respective fluoxetine dose alone.
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Figure 5 Effects of the selective 5-HT2A receptor antagonist M100907
(12.5 mg/kg) or vehicle and fluoxetine (5 mg/kg) or vehicle on inter-
response time (IRT) distributions for rats performing on a DRL 72-s
schedule. The effects for two rats are shown where a significant rightward
shift (typical of most antidepressant drugs) in the IRT distribution occurred
in the M100907þ fluoxetine condition compared to the other three
conditions (po0.001, Kolmorgorov–Smirnov test). The mean IRT for the
conditions shown for rat 74 were 47.4 s (vehicle–vehicle, SD 25.3); 45.6
(fluoxetine, 5 mg/kgþ vehicle, SD 27.0); 49.8 (vehicleþM100907, 12.5mg/
kg, SD 27.4); 68.7 (fluoxetine, 5 mg/kgþM100907, 12.5mg/kg, SD 35.5).
The mean IRT for the conditions shown for rat 77 was 42.6 s (vehicle–
vehicle, SD 18.5); 41.8 (fluoxetine, 5 mg/kgþ vehicle, SD 23.1); 39.8
(vehicleþM100907, 12.5 mg/kg, SD 20.8); 56.3 (fluoxetine, 5 mg/kgþ
M100907, 12.5mg/kg, SD 31.7).
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5-HT Levels: In Vivo Microdialysis Experiments
Following Fluoxetine and M100907
Fluoxetine (5 mg/kg, i.p.) increased the extracellular con-
centrations of 5-HT in prefrontal cortex (Figure 7) as
previously observed (Hervas and Artigas 1998). Since
extracellular 5-HT concentrations have been reported only
for a possibly nonselective dose of M100907 (1000 mg/kg,
i.p.) after fluoxetine administration (Zhang et al, 2000), we
chose to examine 5-HT levels following a low dose of
M100907 (12.5 mg/kg) which had a synergistic behavioral
interaction with fluoxetine. M100907 did not increase
extracellular 5-HT concentrations following fluoxetine
compared to a saline-treated control group (eg, fluoxe-
tine-saline) in the medial or lateral prefrontal cortex
(Figure 7). Two-way ANOVA of these data revealed a
significant effect of time in both areas (F15,90¼ 18.0,
po0.00001 in medial prefrontal cortex; F15,90¼ 12.9,
po0.000001 in lateral prefrontal cortex) but not of the
group or time group interaction. An increase in extra-
cellular 5-HT levels was observed after the administration of
saline and M100907, which is possibly related to the
injection-associated stress. Similar results were also ob-
served for the interaction of M100907 and fluoxetine in the
striatum (not shown).
DISCUSSION
The main finding from the present study using the DRL 72-s
schedule is that simultaneous blockade of 5-HT2A receptors
and SERT results in antidepressant-like efficacy (increased
reinforcement rate, decrease in response rate, and a
rightward shift in the IRT distribution) of greater magni-
tude than would be expected from the additive effects of
either drug administered alone. The most prominent
evidence of a synergistic interaction between M100907 and
fluoxetine was found for effects on the IRT distributions,
while the synergistic effect on the number of reinforcers
obtained was obvious in only one of two separate groups of
subjects tested.
The use of the highly selective 5-HT2A receptor antagonist
M100907 (Kehne et al, 1996) confirmed previous sugges-
tions that selective blockade of 5-HT2A relative to 5-HT2C or
other receptors pharmacologically similar to the 5-HT1
receptor family results in antidepressant-like effects on the
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Figure 6 Effects of the selective 5-HT2A receptor antagonist M100907
(12.5 mg/kg) or vehicle and fluoxetine (5 mg/kg) or vehicle on inter-
response time (IRT) distributions for several rats from a second group
performing on a DRL 72-s schedule. The effects for two rats are shown
where a significant rightward shift (typical of most antidepressant drugs) in
the IRT distribution occurred in the M100907þ fluoxetine condition
compared to the other three conditions (po0.001, Kolmorgorov–Smirnov
test). The mean IRT for the conditions shown for rat 84 were 53.1 s
(vehicle–vehicle, SD 18.7); 56.1 (fluoxetine, 5 mg/kgþ vehicle, SD 24.6);
56.9 (vehicleþM100907, 12.5mg/kg, SD 29.0); 78.1 (fluoxetine, 5 mg/kgþ
M100907, 12.5mgkg, SD 32.4). The mean IRT for the conditions shown for
rat 85 were 35.1 s (vehicle–vehicle, SD 22.1); 33.5 (fluoxetine, 5 mg/kgþ
vehicle, SD 20.3); 36.4 (vehicleþM100907, 12.5mg/kg, SD 23.9); 53.6
(fluoxetine, 5 mg/kgþM100907, 12.5mg/kg, SD 29.9).
Figure 7 Effects of the SSRI fluoxetine (5 mg/kg) and M100907 (12.5 mg/
kg) or saline on 5-HT in dialysates from the mPFC (a) and lPFC (b). All rats
were administered fluoxetine (first arrow) after measuring stable baseline
over four 20 min fractions. Fluoxetine elicited a stable increase of the
extracellular 5-HT concentration in both areas. After 2 h, rats were injected
i.p. with saline (open circles) or M100907 (filled circles) (second arrow).
The injection of saline and M100907 induced a transient increase in 5-HT,
which is most likely associated to the stress of handling the rats and the
injection itself. Data are means7SEM of 4–5 rats/group.
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DRL 72-s schedule (Marek and Seiden, 1988; Marek et al,
1989; Marek and Seiden, 1994). The present results are in
contrast to a popular antidepressant drug screen, the forced
swim or Porsolt test, where selective 5-HT2A antagonists do
not decrease immobility similar to most antidepressant
drugs (Luttinger et al, 1985; Borsini, 1995). Furthermore,
the 5-HT2A antagonist ketanserin failed to potentiate the
anti-immobility effect for subactive doses of fluoxetine,
citalopram, or fluvoxamine in the mouse forced swim test
(Redrobe and Bourin, 1997). However, a recent report that
swim stress induces a profound suppression of head shakes
induced by 5-HT2A receptor activation seriously questions
whether negative effects of 5-HT2A antagonists on the forced
swim test might represent a false negative result due to a
physiological confound with this paradigm (Pericic,
2003).The present antidepressant-like effects of M100907
both alone and in combination with the SSRI fluoxetine are
probably mediated by blockade of central 5-HT2A receptors.
Although M100907 was not administered centrally, pre-
viously a highly selective 5-HT2 receptor antagonist lacking
CNS penetrance (xylamidine) failed to exert an antidepres-
sant-like effect on DRL 72-s behavior (Marek et al, 1989).
The high potency of M100907 on DRL 72-s behavior is in
excellent agreement with the high potency of M100907
(ED50¼ 5mg/kg) in blocking DOI-induced head shakes in
the rat (Schreiber et al, 1995). The present M100907 data are
an important extension of previous pharmacological studies
using the DRL 72-s schedule as this drug does not possess
potent a1-adrenergic blockade and also does not bind to the
tetrabenazine-sensitive vesicular sites or 5-HT1D receptors
as one of the previously tested 5-HT2A antagonists,
ketanserin. Nevertheless, the numerically inferior perfor-
mance of higher M100907 doses (0.3 and 1.0 mg/kg)
compared to the maximal changes in reinforcement and
response rate at 0.1 mg/kg may reflect decreased pharma-
cological specificity at these higher doses such as 5-HT2C
receptors (Kehne et al, 1996; Marek and Seiden, 1994) or a
preferential activation of a subpopulation of 5-HT2A
receptors in different cellular compartments and/or pheno-
types (Aghajanian and Marek, 1997; Jakab and Goldman-
Rakic, 1998, 2000; Miner et al, 2003; Willins et al, 1997;
Zhou and Hablitz, 1999). Other investigators have reported
that 5-HT2C receptor agonist activity is associated with
increases in the reinforcement rate and decreases in the
response rate in rats performing on a DRL 72-s schedule
(Martin et al, 1998), thus blockade of 5-HT2C receptors may
counter ‘antidepressant-like’ effects of 5-HT2A receptor
antagonists on DRL 72-s behavior.
The apparent synergistic effects of M100907 and fluox-
etine on rats performing on the DRL 72-s schedule argue for
a pharmacodynamic rather than a pharmacokinetic me-
chanism underlying this behavioral drug–drug interaction.
The lack of an effect of M100907 on the fluoxetine (5 mg/kg,
ip)-induced increase in extracellular 5-HT in both the
prefrontal cortex and striatum is not consistent with
M100907 altering fluoxetine metabolism. However, drug
levels for fluoxetine and M100907 were not analyzed to rule
out such a pharmacokinetic interaction.
To our knowledge, this represents the first preclinical
report suggesting that selective blockade of 5-HT2A
receptors may have a synergistic effect with blockade of
SERT. SSRIs have minimal effects on the IRT distribution
that appears to be qualitatively different from the cohesive
rightward shifts induced by TCAs, MAOIs, and atypical
antidepressants (O’Donnell and Seiden, 1982; Richards and
Seiden, 1991; Seiden et al, 1985; Sokolowski and Seiden,
1999). In contrast, the effects of selective 5-HT2A receptor
blockade on IRT distributions of rats performing on the
DRL 72-s schedule appears qualitatively similar to TCAs,
MAOIs, and ‘atypical’ antidepressants (which do not
appreciably block monoamine transporters or MAO). The
rightward shifts in the IRT distribution were most marked
for the combinations of M100907 and fluoxetine. The
absence of an interaction of fluoxetine and M100907 at
increasing extracellular 5-HT in the mPFC, lateral prefrontal
cortex, and striatum is not consistent with the hypothesis
that a synergistic increase in extracellular 5-HT is the
pharmacodynamic mechanism mediating the synergistic
behavioral effect of the 5-HT2A antagonist and the SSRI.
These present in vivo dialysis results obtained in Wistar rats
with a lower dose of M100907 are similar to past results
obtained with a higher dose of M100907 (1 mg/kg, s.c.) in
Sprague–Dawley rats (Zhang et al, 2000).
The present behavioral interactions between 5-HT2A
receptor blockade and SERT inhibition on DRL behavior
would appear consistent with the general excitatory actions
of 5-HT2A receptors and inhibitory effects of 5-HT1-like
receptors in areas such as the mPFC and neocortex.
Activation of 5-HT2A receptors depolarizes pyramidal
neurons (Araneda and Andrade, 1991; Tanaka and North,
1993) and enhances their firing activity (Puig et al, 2003), an
effect that may involve glutamate release from thalamocor-
tical afferents (Marek et al, 2001). In contrast, activation of
5-HT1A receptors hyperpolarizes pyramidal neurons (Ara-
neda and Andrade, 1991; Ashby et al, 1994) and activation
of 5-HT1B/1D heteroceptors can decrease release of gluta-
mate and/or other excitatory amino acids (Marcoli et al,
1999; Maura et al, 1998; Tanaka and North, 1993). 5-HT2A
and 5-HT1A receptors are coexpressed by a large population
of PFC neurons (Amargos-Bosch et al, 2004) and opposing
effects of the activation of both receptors by 5-HT on
pyramidal cell activity have been reported (Amargos-Bosch
et al, 2004; Araneda and Andrade, 1991; Ashby et al, 1994).
The 5-HT1A antagonist WAY-100635 previously has been
found to block the increase in the reinforcement rate
induced by a 10 mg/kg dose of fluoxetine (Cousins and
Seiden, 2000). However, these same doses of WAY-100635
also produced a substantial enhancement of the response-
rate decreasing effect of the 10 mg/kg fluoxetine dose.
Nonetheless, it is possible that the administration of
M100907 resulted in an enhanced 5-HT1A receptor-
mediated transmission in PFC. However, additional 5-HT
receptors may contribute to the apparent functional
antagonism of 5-HT2A receptor-mediated effects that can
be seen from electrophysiological studies both from in vivo
preparations and prefrontal cortical slice preparations
(Aghajanian and Marek, 1997, 1999; Lakoski and Aghaja-
nian, 1985; Marek, 2000).
A recent review has discussed a number of double-blind,
placebo-controlled studies which together suggest that a
combination of drugs which block both the 5-HT2 family of
receptors and SERT would have greater antidepressant
efficacy than SSRIs alone (Marek et al, 2003). The initial
report on the olanzapine–fluoxetine combination in treat-
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ment-resistant, nonpsychotic unipolar depression found
that within 1 week of adding on 5 mg/day of olanzapine
onto ongoing fluoxetine treatment, patients had a superior
response to those patients having placebo added on to
ongoing fluoxetine treatment (Shelton et al, 2001). The
superior efficacy of the olanzapine–fluoxetine combination
in bipolar I depression compared to olanzapine alone or
placebo further supports the hypothesis that the blockade of
a 5-HT2 receptor and SERT results in superior antidepres-
sant efficacy than simpl blockade of SERT alone (Tohen
et al, 2003) The major limitation in extrapolating to the
critical receptor(s) underlying this boost in clinical efficacy
is the rich pharmacology for mianserin, mirtazapine, and
olanzapine. All three drugs would be expected to block the
5-HT2C receptor at exposures similar to those blocking 5-
HT2A receptors. All three drugs are even more potent at the
histamine H1 receptor than the 5-HT2 family of receptors.
While mirtazapine and mianserin also potently block alpha-
2 noradrenergic receptors, mirtazapine appears to have a
wider profile of action on noradrenergic autoreceptors than
does mianserin. Olanzapine appears to be more potent in
blocking 5-HT2A receptors than dopamine D2 receptors
from in vivo PET studies with human subjects (Kapur et al,
1999), in agreement with in vitro or ex vivo binding data
with native rat or cell lines transfected with human
receptors (Bymaster et al, 1996; Schotte et al, 1996).
Multiple lines of evidence are consistent with the
hypothesis that blockade of 5-HT2A receptors might
enhance the therapeutic effectiveness of SSRIs. First and
foremost, a number of placebo controlled trials have found
that addition of drugs, which share a common pharmaco-
logical action of 5-HT2 receptor blockade (eg, mianserin,
mirtazapine and olanzapine), appear to enhance the
antidepressant efficacy of SSRIs (Marek et al, 2003). Second,
downregulation of 5-HT2A receptors is a common and
reasonably specific characteristic for known antidepressant
drugs (Peroutka and Snyder, 1980), although some con-
troversy exists regarding the effects of SSRIs. Third, a trend
exists for upregulation of 5-HT2A receptor binding in
discrete prefrontal cortical regions of suicide victims from
postmortem studies (Pandey et al, 2002; Stockmeier et al,
1997). Fourth, blockade of 5-HT2A receptors is one of the
most common and potent shared pharmacological actions
for a number of antidepressants (Marek et al, 1992) which
do not appear to have antidepressant efficacy in patients
due to blockade of SERT (serotonin transporters), NET
(norepinephrine transporters), or monoamine oxidase
(MAO; eg, mirtazapine, mianserin, nefazodone, trazodone,
and iprindole). Fifth, intolerance to high doses of parox-
etine in elderly patients due to difficulty with arousal,
concentration, agitation, and sleep disturbances appears to
be related to a single-nucleotide polymorphism (SNP) in the
5-HT2A receptor gene (Murphy et al, 2003). One cannot
conclude whether this pharmacological effect reflects an
enhancement of paroxetine-induced adverse events or a
deterioration of a cluster of core depressive symptoms.
Sixth, activation of 5-HT2A receptors appears to result
predominantly in excitatory actions in the neocortex and
prefrontal cortex in contrast to the widespread inhibitory
actions of 5-HT itself (Aghajanian and Marek, 1997;
Araneda and Andrade, 1991; Ashby et al, 1994; Tanaka
and North, 1993).
In summary, the present results suggest that selective
blockade of 5-HT2A receptors may complement the
behavioral effects of SERT inhibition. These behavioral
observations would appear consistent with the general
opposing effects of 5-HT2A and many non-5-HT2A receptors
throughout cortical-thalamic-striatal-amygdaloid circuits.
One important implication of the present studies for clinical
investigation is whether blockade of 5-HT2A receptors
contributes to the enhancement of antidepressant effects
of SSRIs found with mirtazapine, mianserin, olanzapine,
and risperidone. Obviously, testing the combination of a
highly selective 5-HT2A receptor antagonist like M100907
together with an SSRI or a new chemical entity with
selective blockade of both 5-HT2A and SERT in the same
molecule (Puller et al, 2000; Schmidt et al, 2001) would be a
critical clinical experiment to test this hypothesis. A second
implication open for future studies is whether selective
blockade of 5-HT2A receptors can also have an additive or
synergistic action in the treatment of other diverse
neuropsychiatric syndromes for which SSRIs are a useful
therapeutic modality (Marek et al, 2003).
ACKNOWLEDGEMENTS
This work was previously presented at the 2001 Society for
Neuroscience meeting (San Diego, CA) and the 2001
meeting of the American College of Neuropsychopharma-
cology (San Juan, Puerto Rico). This study was supported
by PHS Grants K08 MH01551, R01 MH62186, a NARSAD
Young Investigator Award (1999 Fairfax Investigator
Award), the state of Connecticut (GJM), and National
Institutes of Health Grants FIS 01/1147 and SAF2001-2133
(FA) We appreciate Dr Younglim Lee’s review of the
manuscript. We thank Nigel Henry, Sara Heron, Andrew
Kwak, Megan Lennon, Boting Zhang, and Leticia Campa for
technical assistance. We also thank Leslie Rosello for
secretarial assistance.
REFERENCES
Adell A, Artigas F (1998). A microdialysis study of the in vivo
release of 5-HT in the median raphe nucleus of the rat. Br J
Pharmacol 125: 1361–1367.
Aghajanian GK, Marek GJ (1997). Serotonin induces excitatory
postsynaptic potentials in apical dendrites of neocortical
pyramidal cells. Neuropharmacology 36: 589–599.
Aghajanian GK, Marek GJ (1999). Serotonin, via 5-HT2A receptors,
increases EPSCs in layer V pyramidal cells of prefrontal cortex
by an asynchronous mode of glutamate release. Brain Res 825:
161–171.
Amargos-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A,
Celada P et al (2004). Co-expression and in vivo interaction of
serotonin1a and serotonin2a receptors in pyramidal neurons of
prefrontal cortex. Cereb Cortex 14: 281–299.
Araneda R, Andrade R (1991). 5-Hydroxytryptamine2 and 5-
Hydroxytryptamine1A receptors mediate opposing responses on
membrane excitability in rat association cortex. Neuroscience 40:
399–412.
Ashby CR, Edwards E, Wang RY (1994). Electrophysiological
evidence for a functional interaction between 5-HT1A and
5-HT2A receptors in the rat medial prefrontal cortex: an
iontophoretic study. Synapse 17: 173–181.
5-HT2A antagonist and SSRI interactions
GJ Marek et al
2213
Neuropsychopharmacology
Borsini F (1995). Role of the serotonergic system in the forced
swimming test. Neurosci Biobehav Rev 19: 377–395.
Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA,
Tye NC et al (1996). Radioceptor binding profile of the
atypical antipsychotic olazepine. Neuropsychopharmacology
14: 87–96.
Cousins MS, Seiden LS (2000). The serotonin-1A receptor
antagonist WAY-100635 modifies fluoxetine’s antidepressant-
like profile on the differential reinforcement of low rates 72-s
schedule in rats. Psychopharmacology 148: 438–442.
Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H,
Heninger GR (1990). Serotonin function and the mechanism of
antidepressant action. Reversal of antidepressant-induced re-
mission by rapid depletion of plasma tryptophan. Arch Gen
Psychiatry 47: 411–418.
Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno
FA et al (1999). Tryptophan-depletion challenge in depressed
patients treated with desipramine or fluoxetine: implications for
the role of serotonin in the mechanism of antidepressant action.
Biol Psychiatry 46: 212–220.
Hervas I, Artigas F (1998). Effect of fluoxetine on extracellular
5-hydroxytryptamine in rat brain. Role of autoreceptors. Eur J
Pharmacol 358: 9–18.
Hirose S, Ashby CRJ (2002). An open pilot study combining
risperidone and a selective serotonin reuptake inhibitor as initial
antidepressant therapy. J Clin Psychiatry 63: 733–736.
Jakab RL, Goldman-Rakic PS (1998). 5-HT2A serotonin receptors
in the primate cerebral cortex: possible site of action of
hallucinogens in pyramidal cell apical dendrites. Proc Natl Acad
Sci USA 95: 735–740.
Jakab RL, Goldman-Rakic PS (2000). Segregation of serotonin 5-
HT2A and 5-HT3 receptors in inhibitory circuits of the primate
cerebral cortex. J Comp Neurol 417: 337–348.
Kapur S, Zipursky RB, Remington G (1999). Clinical and
theoretical implications of 5-HT2 and D2 receptor occupancy
of clozapine, risperidone, and olanzapine in schizophrenia. Am J
Psychiatry 156: 286–293.
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ
et al (1996). Preclinical characterization of the potential of the
putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A
antagonist with a favorable CNS safety profile. J Pharmacol Exp
Ther 277: 968–981.
Lakoski JM, Aghajanian GK (1985). Effects of ketanserin on
neuronal responses to serotonin in the prefrontal cortex, lateral
geniculate and dorsal raphe nucleus. Neuropharmacology 24:
265–273.
Luttinger D, Freedman M, Hamel L, Ward SJ, Perrone M (1985).
The effects of serotonin antagonists in a behavioral despair
procedure in mice. Eur J Pharmacol 107: 53–58.
Marcoli M, Maura G, Munari C, Ruelle A, Raiteri M (1999).
Pharmacological diversity between native human 5-HT1B and
5-HT1D receptors sited on different neurons and involved
in different functions. Br J Pharmacol 126: 607–612.
Marek GJ (2000). A novel approach to the identification of
psychiatric drugs: serotonin–glutamate interactions in the
prefrontal cortex. CNS Drug Rev 6: 205–217.
Marek GJ, Carpenter LL, McDougle CJ, Price LH (2003).
Synergistic action of 5-HT2A antagonists and selective serotonin
reuptake inhibitors in neuropsychiatric disorders. Neuropsycho-
pharmacology 28: 402–412.
Marek GJ, Li AA, Seiden LS (1989). Selective 5-hydroxytrypta-
mine2 antagonists have antidepressant-like effects on differen-
tial-reinforcement-of-low-rate 72-second schedule. J Pharmacol
Exp Ther 250: 52–59.
Marek GJ, McDougle CJ, Price LH, Seiden LS (1992). A comparison
of trazodone and fluoxetine: implications for a serotonergic
mechanism of antidepressant action. Psychopharmacology
109: 2–11.
Marek GJ, Seiden LS (1988). Effects of selective 5-hydroxytrypta-
mine-2 and nonselective 5-hydroxytryptamine antagonists on
the differential-reinforcement-of-low-rate 72-second schedule. J
Pharmacol Exp Ther 244: 650–658.
Marek GJ, Seiden LS (1994). Antidepressant drug screens and the
serotonin system. In: Palomo T, Archer T (eds). Strategies for
Studying Brain Disorders: Depressive, Anxiety and Drug Abuse
Disorders. Vol 1. Farrand Press: London. pp 23–40.
Marek GJ, Wright RA, Gewirtz JC, Schoepp DD (2001). A major
role for thalamocortical afferents in serotonergic hallucinogen
receptor function in neocortex. Neuroscience 105: 113–126.
Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ et al
(1998). 5-HT2C receptor agonists: pharmacological char-
acteristics and therapeutic potential. J Pharmacol Exp Ther
286: 913–924.
Maura G, Marcoli M, Tortarolo M, Andrioli GC, Raiteri M (1998).
Glutamate release in human cerebral cortex and its modulation
by 5-hydroxytryptamine acting at h 5HT1D receptors. Br J
Pharmacol 123: 45–50.
Miner LAH, Backstrom JR, Sanders-Bush E, Sesack SR (2003).
Ultrastructural localization of serotonin2A receptors in the
middle layers of the rat prelimbic prefrontal cortex. Neuroscience
116: 107–117.
Murphy GMJ, Kremer C, Rodriques HE, Schatzberg AF (2003).
Pharmacogenetics of antidepressant medication intolerance. Am
J Psychiatry 160: 1830–1835.
O’Connor M, Silver H (1998). Adding risperidone to selective
serotonin reuptake inhibitor improves chronic depression. J Clin
Psychopharmacol 18: 89–90.
O’Donnell JM, Marek GJ, Seiden LS (2005). Antidepressant effects
assessed using behavior maintained under a differential-
reinforcement-of-low-rate (DRL) operant schedule. Neurosci
Biobehav Rev (in press).
O’Donnell JM, Seiden LS (1982). Effects of monoamine oxidase
inhibitors on performance during differential reinforcement of
low response rate. Psychopharmacology 78: 214–218.
Ostroff RB, Nelson JC (1999). Risperidone augmentation of SSRIs
in major depression. J Clin Psychiatry 60: 256–259.
Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, Pesold C
et al (2002). Higher expression of 5-HT2A receptors in the
postmortem brains of teenage suicide victims. Am J Psychiatry
159: 419–429.
Paxinos G, Watson C (1986). The Rat Brain in Stereotoxic
Coordinates. Academic Press: Orlando, FL.
Pericic D (2003). Swim stress inhibits 5-HT2A receptor-mediated
head twitch behavior in mice. Psychopharmacology 167: 373–379.
Peroutka SJ, Snyder SH (1980). Long-term antidepressant treat-
ment decreases spiroperidol-labeled serotonin receptor binding.
Science 210: 88–90.
Puig MV, Celada P, Diaz-Mataix L, Artigas F (2003). In vivo
modulation of the activity of pyramidal neurons in the rat
medial prefrontal cortex by 5-HT2A receptors. Relationship to
thalamocortical afferents. Cereb Cortex 13: 870–882.
Puller IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S
(2000). LY367265, an inhibitor of the 5-hydroxytryptamine
transporter and 5-hydroxytryptamine 2A receptor antagonist: a
comparison with the antidepressant, nefazodone. Eur J Pharma-
col 407: 39–46.
Redrobe JP, Bourin M (1997). Partial role of 5-HT2 and 5-HT3
receptors in the activity of antidepressants in the mouse forced
swimming test. Eur J Pharmacol 325: 129–135.
Richards JB, Seiden LS (1991). A quantitative interresponse time
analysis of DRL performance differentiates similar effects of the
antidepressant desipramine and the novel anxiolytic gepirone.
J Exp Anal Behav 56: 173–192.
Schmidt CJ, Fox CB, Harms JF, Wylie P, Seegar TF, Guanowsky V
et al (2001). CP-646,781: a potent dual SSRI/5-HT2A receptor
agonist. Socr Neurosci Abstr 27: Program no. 665-17.
5-HT2A antagonist and SSRI interactions
GJ Marek et al
2214
Neuropsychopharmacology
Schotte A, Janssen PFM, Gommeren W, Luyten WH, Van Gompel
P, Lesage AS et al (1996). Risperidone compared with new and
reference antipsychotic drugs: in vitro and in vivo receptor
binding. Psychopharmacology 124: 57–73.
Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ
(1995). 1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-in-
duced head-twitches in the rat are mediated by 5-hydroxy-
tryptamine(5-HT)2A receptors: modulation by novel 5-HT2A/2C
antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol
Exp Ther 273: 101–112.
Seiden LS, Dahms JL, Shaughnessy RA (1985). Behavioral screen
for antidepressants: the effects of drugs and electroconvulsive
shock on performance under a differential-reinforcement-of-
low-rate schedule. Psychopharmacology 86: 55–60.
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs
TG et al (2001). A novel augmentation strategy for treating
resistant major depression. Am J Psychiatry 158: 131–134.
Sokolowski JD, Seiden LS (1999). The behavioral effects of
sertraline, fluoxetine, and paroxetine differ on the differential-
reinforcement-of-low-rate 72-second operant schedule in the rat.
Psychopharmacology 147: 153–161.
Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson
PA, Meltzer HY (1997). Serotonin receptors in suicide victims
with major depression. Neuropsychopharmacology 16: 162–173.
Tanaka E, North RA (1993). Actions of 5-hydroxytryptamine
on neurons of the rat cingulate cortex. J Neurophysiol 69:
1749–1757.
Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al
(2003). Efficacy of olanzapine and olanzapine–fluoxetine com-
bination in the treatment of bipolar I depression. Arch Gen
Psychiatry 60: 1079–1088.
Willins DL, Deutch AY, Roth BL (1997). Serotonin 5-HT2A
receptors are expressed on pyramidal cells and interneurons in
the rat cortex. Synapse 27: 79–82.
Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD et al
(2000). Synergistic effects of olanzapine and other antipsychotic
agents in combination with fluoxetine on norepinephrine and
dopamine release in rat prefrontal cortex. Neuropsychopharma-
cology 23: 250–262.
Zhou F-M, Hablitz JJ (1999). Activation of serotonin receptors
modulates synaptic transmission in rat cerebral cortex. J
Neurophysiol 82: 2989–2999.
5-HT2A antagonist and SSRI interactions
GJ Marek et al
2215
Neuropsychopharmacology
